Compare Cassava Sciences Inc (FLNA) vs Lockheed Martin Corporation (LMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Lockheed Martin Corporation — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Lockheed Martin Corporation trades at $516.25 (market cap $118.62B). The key difference: Lockheed Martin Corporation is far larger — about 2232.2× Cassava Sciences Inc's market cap, and Lockheed Martin Corporation pays a 2.68% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | LMT | |
|---|---|---|
Market Cap | $53.14M | $118.62B |
Sector | Health | Industrials |
52-Week High | $4.64 | $676.70 |
52-Week Low | $1.09 | $410.74 |
Enterprise Value | -$33.43M | $137.42B |
Dividend Yield | — | 2.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Lockheed Martin (LMT) trades at $514.99, down 1.09% on the day, with technical indicators showing bearish momentum despite neutral oscillators. The company maintains strong fundamentals with $75.05B in 2025 revenue and a 6.38% net margin, though recent earnings misses in Q4 2025 and Q1 2026 have tempered near-term optimism. Analyst consensus remains bullish with a $614 price target, supported by a massive $194B backlog and expanding defense budgets globally.
LMT presents a compelling value opportunity with significant upside to analyst targets, driven by sustained defense spending and technological leadership. However, execution risks from recent earnings misses and competitive pressures in naval and space markets warrant caution. The stock's current valuation at 24.91 P/E offers reasonable entry for long-term investors seeking defense exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →
